Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

8432.TWO

Strong BuyFull HouseFLAG

TSH Biopharm Corporation Limited · Healthcare · Taiwan · $62M · Avg Vol: $55K/d

100
StockRank
Get insider-trade alerts
Q
82
V
85
M
59
P/E (TTM)
11.6x
ROE
13.4%
D/E
0.0x
Dividend %
5.2%
Dir. Trades · 180d
None →
Buybacks · 180d
None →
AI CONVICTION THESIS

TSH Biopharm operates in the critical path of regionalized pharma supply chains in Taiwan. The thematic tailwind is compelling as regional security becomes paramount, but the fund requires more granular data on their specific competitive advantages in a crowded generic/specialty market.

COMPANY DESCRIPTION

TSH Biopharm Corporation Limited is a specialty pharmaceutical company focused on the development, licensing, and commercialization of therapeutics for cardiovascular, gastrointestinal, and autoimmune diseases. The company's competitive moat lies in its proven track record of navigating local regulatory pathways and its established marketing network across East Asian hospitals. TSH Biopharm operates as a high-margin, asset-light pharmaceutical player utilizing strategic global in-licensing.

FINANCIAL SUMMARY (TWD)

Year20212022202320242025CAGRTTM
Revenue—741.1M810.9M1.1B1.3B21.7%1.4B
EPS (TWD)1.231.611.612.953.6331.0%4.38
Shares—38.4M38.4M38.4M38.4M0.0%38.4M
Debt—63.9M7.8M37.0M26.4M-25.5%15.0M
Equity—1.1B1.1B1.4B1.4B8.3%—
Op CF—34.4M33.9M183.8M139.5M59.5%278.5M
Inv CF—33.4M161.0M-110.4M-164.8M——
Fin CF—-89.4M-107.2M-61.7M-98.5M——
Loading 1Y...
PRICE (1Y)+3.1%
1.551.571.581.601.62Jul 29Aug 19Sep 8
SMA 50SMA 200

Close
$1.60
RSI (14)
54.8
52W High
$1.79
From 52W High
0.9%

SCORE BREAKDOWN

Quality
82
ROIC
13.7%82.7
ROE
13.4%80.7
GP/Assets
36.8%74.9
Op. Margin
22.2%86.0
FCF/Assets
11.5%89.6
Piotroski
784.3
Int. Cover
50.0x89.4
D/E Ratio
0.01x85.0
Current Ratio
4.33x66.4
Value
85
P/E (TTM)
11.6x83.4
EV/EBITDA
4.4x93.6
P/FCF
8.6x85.5
P/B
1.4x74.9
P/S
1.4x76.0
Div Yield
5.2%90.3
Momentum
59
52W High %
89%83.7
RS 6M
-37%22.5
SMA 50/200
0.99x57.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
75%80.3

FUNDAMENTALS

Market Cap
$62M
P/E (Forward)
—
Gross Margin
51.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 8432.TWO are excluded.

TickerCompanyMkt CapStockRankSignal
8432.TWOTSH Biopharm Corporation Limited(you)$62M100Strong Buy
1731.TWMaywufa Company Ltd.$88M92Strong Buy
1720.TWStandard Chemical & Pharmaceutical Co., Ltd.$351M95Strong Buy
3705.TWYungShin Global Holding Corporation$471M97Strong Buy
1707.TWGrape King Bio Ltd$418M93Strong Buy
1760.TWPanion & Bf Biotech Inc.$158M71Buy
4105.TWOTTY Biopharm Company Limited$612M95Strong Buy
3054.TWLIWANLI Innovation Co., Ltd.$145M65Buy
4746.TWFormosa Laboratories, Inc.$188M68Buy
4127.TWOTien Liang BioTech Co., Ltd.$114M39Hold

Peer medians: ROE 4.1% · P/E 15.8x · Gross margin 41.6%

TSH Biopharm Corporation Limited (8432.TWO): Stock Score Summary

TSH Biopharm Corporation Limited (8432.TWO) has a MoatMap StockRank of 100/100 based on Quality (82/100), Value (85/100), and Momentum (59/100) factor scores. The current signal is STRONG BUY. TSH Biopharm operates in the critical path of regionalized pharma supply chains in Taiwan. The thematic tailwind is compelling as regional security becomes paramount, but the fund requires more granular data on their specific competitive advantages in a crowded generic/specialty market.

TSH Biopharm Corporation Limited is a specialty pharmaceutical company focused on the development, licensing, and commercialization of therapeutics for cardiovascular, gastrointestinal, and autoimmune diseases. The company's competitive moat lies in its proven track record of navigating local regulatory pathways and its established marketing network across East Asian hospitals. TSH Biopharm operates as a high-margin, asset-light pharmaceutical player utilizing strategic global in-licensing.

Key Financial Metrics

Price$1.60
Market Cap$62M
P/E (TTM)11.57
Price/Book1.38
Return on Equity13.4%
Return on Invested Capital13.7%
Debt/Equity0.01x
Gross Margin51.7%
Operating Margin22.2%
Revenue Growth22.8%
Dividend Yield5.2%
Free Cash Flow$7M

TSH Biopharm Corporation Limited operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Taiwan).

Frequently Asked Questions

What is TSH Biopharm Corporation Limited’s (8432.TWO) StockRank?
MoatMap’s StockRank for TSH Biopharm Corporation Limited (8432.TWO) is 100/100, with a Strong Buy signal. It is a composite of Quality (82), Value (85), and Momentum (59) factor ranks across MoatMap’s 20,000+ stock universe.
Does TSH Biopharm Corporation Limited have an economic moat?
TSH Biopharm Corporation Limited (8432.TWO) has a Quality factor score of 82/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is TSH Biopharm Corporation Limited a buy, hold, or sell?
MoatMap’s current signal for TSH Biopharm Corporation Limited (8432.TWO) is Strong Buy, based on a StockRank of 100/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is TSH Biopharm Corporation Limited in?
TSH Biopharm Corporation Limited (8432.TWO) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Taiwan).
Browse all ranked stocks8432.TWO deep dive reportAI ChampionsHow we score stocksSense-check another stock